<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9795">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979431</url>
  </required_header>
  <id_info>
    <org_study_id>ALX0171-C201</org_study_id>
    <secondary_id>2016-001651-49</secondary_id>
    <nct_id>NCT02979431</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection</brief_title>
  <acronym>Respire</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study of ALX-0171 in Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the anti-viral effect and safety of different doses of
      inhaled ALX-0171 in subjects hospitalized for Respiratory Syncytial Virus Lower Respiratory
      Tract Infection (RSV LRTI). The secondary objective is to evaluate the clinical activity,
      pharmacokinetic (PK) properties, pharmacodynamic (PD) effect and immunogenicity of different
      doses of inhaled ALX-0171.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time for viral load to drop below assay quantification limit (BQL)</measure>
    <time_frame>From day of first dose to 14 days after first dose</time_frame>
    <description>Time needed for the viral load to drop below the assay quantification limit (time-to-BQL) in nasal swab specimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as measured by the incidence of treatment-emergent adverse events, clinical laboratory parameters, vital signs and physical examination</measure>
    <time_frame>From 1 day before first dose to 28 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Severity Score</measure>
    <time_frame>From 1 day before first dose to 28 days after first dose</time_frame>
    <description>Evolution over time in Global Severity Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response</measure>
    <time_frame>From 1 day before first dose to 28 days after first dose</time_frame>
    <description>Evaluation of the clinical response of the subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics as measured by the concentration of ALX-0171 in serum</measure>
    <time_frame>Day 2 - Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution over time of viral load in nasal swab specimens</measure>
    <time_frame>From day of first dose to 14 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by the concentration of anti-ALX 0171 antibodies in serum</measure>
    <time_frame>From 1 day before first dose to 14 days after first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Respiratory Syncytial Virus Lower Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>ALX-0171 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of ALX-0171 Dose 1 once daily for 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0171 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of ALX-0171 Dose 2 once daily for 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0171 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of ALX-0171 Dose 3 once daily for 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhalation of Placebo once daily for 3 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0171 Dose 1</intervention_name>
    <arm_group_label>ALX-0171 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0171 Dose 2</intervention_name>
    <arm_group_label>ALX-0171 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0171 Dose 3</intervention_name>
    <arm_group_label>ALX-0171 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is otherwise healthy, but is hospitalized for and clinically diagnosed with
             RSV LRTI

          -  Subject has a positive RSV diagnostic test.

          -  Symptoms likely related to RSV infection have appeared within 4 days of screening and
             are not yet improving at screening.

        Others as defined in the protocol

        Exclusion Criteria:

          -  Subject is known to have significant comorbidities

          -  Subject is known to be human immunodeficiency virus (HIV)-positive

          -  Subject is known to be immunocompromised

          -  Subject has or is suspected to have an active, clinically relevant concurrent
             infection Others as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ablynx Clinical Department</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ablynx NV Belgium</last_name>
    <phone>+32 9 262 00 00</phone>
    <email>clinicaltrials@ablynx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ablynx NV Belgium</last_name>
      <email>clinicaltrials@ablynx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>November 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
